Yale JF, Catarig AM, Grau K, et al. - According to SURE Canada study, a multicenter, prospective, observational study, patients treated with once-weekly (OW) semaglutide in routine clinical practice had clinically meaningful improvements in HbA1c, body weight (BW) and other outcomes, indicating that semaglutide should be used in routine clinical practice.

• Adults with type 2 diabetes who had one or more recorded HbA1c levels 12 weeks or less before starting semaglutide were eligible to participate.

• In total, 452 patients started taking semaglutide and 356 finished the study.

• The 452 patients had a mean HbA1c of 8.1% at baseline, with 86 (19.0%) having an HbA1c of less than 7.0%.

• At end of study (EOS), the mean dose of semaglutide was 0.76 ± 0.31 mg.

• HbA1c was reduced by 0.9%-point on average. BW was lowered by 4.3 kg on average.

• At EOS, 46.9% of patients had an HbA1c of less than 7.0%, 40.9% had a WL of 5% or more, and 24.1% had the composite endpoint.

• From baseline to EOS, patient-reported outcomes improved.

• There were no new safety concerns noted.